Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling.

Torrens G, Hernández SB, Ayala JA, Moya B, Juan C, Cava F, Oliver A.

mSystems. 2019 Dec 3;4(6). pii: e00524-19. doi: 10.1128/mSystems.00524-19.

PMID:
31796566
2.

Desquamating-nonpigmenting with onycholysis fixed drug eruption in a child due to amoxicillin. Cross-reactivity study.

Moya B, Vera A, Bazire R, Betancor D, Rodríguez Del Río P, Escudero C, Ibáñez MD.

J Investig Allergol Clin Immunol. 2019 Nov 21:0. doi: 10.18176/jiaci.0466. [Epub ahead of print] No abstract available.

3.

Resource recovery and biochar characteristics from full-scale faecal sludge treatment and co-treatment with agricultural waste.

Krueger BC, Fowler GD, Templeton MR, Moya B.

Water Res. 2019 Nov 1;169:115253. doi: 10.1016/j.watres.2019.115253. [Epub ahead of print]

4.

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.

Jiao Y, Moya B, Chen MJ, Zavascki AP, Tsai H, Tao X, Sutaria DS, Louie A, Boyce JD, Deveson Lucas D, Kim TH, Tsuji BT, Bonomo RA, Drusano GL, Bulitta JB.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00425-19. doi: 10.1128/AAC.00425-19. Print 2019 Jul.

PMID:
30988147
5.

In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.

Moya B, Barcelo IM, Cabot G, Torrens G, Palwe S, Joshi P, Umarkar K, Takalkar S, Periasamy H, Bhagwat S, Patel M, Bou G, Oliver A.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00128-19. doi: 10.1128/AAC.00128-19. Print 2019 May.

6.

First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.

Jiao Y, Kim TH, Tao X, Kinzig M, Landersdorfer CB, Drescher SK, Sutaria DS, Moya B, Holzgrabe U, Sörgel F, Bulitta JB.

Eur J Pharm Sci. 2018 Oct 15;123:416-428. doi: 10.1016/j.ejps.2018.07.054. Epub 2018 Aug 1.

PMID:
30076955
7.

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP, Shin BS, Drusano GL, Sörgel F, Landersdorfer CB.

Clin Pharmacokinet. 2019 Feb;58(2):143-156. doi: 10.1007/s40262-018-0678-x. Review.

PMID:
29936678
8.

First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae.

Sutaria DS, Moya B, Green KB, Kim TH, Tao X, Jiao Y, Louie A, Drusano GL, Bulitta JB.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00282-18. doi: 10.1128/AAC.00282-18. Print 2018 Jun.

9.

Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.

Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01238-17. doi: 10.1128/AAC.01238-17. Print 2017 Nov.

10.

Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system.

Torrens G, Pérez-Gallego M, Moya B, Munar-Bestard M, Zamorano L, Cabot G, Blázquez J, Ayala JA, Oliver A, Juan C.

PLoS One. 2017 Jul 25;12(7):e0181932. doi: 10.1371/journal.pone.0181932. eCollection 2017.

11.

WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.

Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02529-16. doi: 10.1128/AAC.02529-16. Print 2017 Jun.

12.

Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway?

Pérez-Gallego M, Torrens G, Castillo-Vera J, Moya B, Zamorano L, Cabot G, Hultenby K, Albertí S, Mellroth P, Henriques-Normark B, Normark S, Oliver A, Juan C.

MBio. 2016 Oct 25;7(5). pii: e01783-16. doi: 10.1128/mBio.01783-16.

13.

Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MÁ, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Plesiat P, Oliver A.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7415-7423. Print 2016 Dec.

14.

Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.

Rojo-Molinero E, Macià MD, Rubio R, Moyà B, Cabot G, López-Causapé C, Pérez JL, Cantón R, Oliver A.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2912-22. doi: 10.1128/AAC.00196-16. Print 2016 May.

15.

Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.

Cabot G, Zamorano L, Moyà B, Juan C, Navas A, Blázquez J, Oliver A.

Antimicrob Agents Chemother. 2016 Jan 4;60(3):1767-78. doi: 10.1128/AAC.02676-15.

16.

Possible land management uses of common cypress to reduce wildfire initiation risk: a laboratory study.

Della Rocca G, Hernando C, Madrigal J, Danti R, Moya J, Guijarro M, Pecchioli A, Moya B.

J Environ Manage. 2015 Aug 15;159:68-77. doi: 10.1016/j.jenvman.2015.05.020. Epub 2015 Jun 2.

PMID:
26046989
17.

Infections After Liver Transplantation: A Retrospective, Single-center Study.

Antunes M, Teixeira A, Fortuna P, Moya B, Martins A, Bagulho L, Pereira JP, Bento L, Perdigoto R, Barroso E, Marcelino P.

Transplant Proc. 2015 May;47(4):1019-24. doi: 10.1016/j.transproceed.2015.03.009.

PMID:
26036509
18.

Liver depurative techniques: a single liver transplantation center experience.

Rodrigues J, Castro SG, Moya B, Fortuna P, Martins A, Pereira JP, Bento L, Perdigoto R, Barroso E, Marcelino P.

Transplant Proc. 2015 May;47(4):996-1000. doi: 10.1016/j.transproceed.2015.03.016.

PMID:
26036503
19.

Role of Pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins in AmpC expression, β-lactam resistance, and peptidoglycan structure.

Ropy A, Cabot G, Sánchez-Diener I, Aguilera C, Moya B, Ayala JA, Oliver A.

Antimicrob Agents Chemother. 2015 Jul;59(7):3925-34. doi: 10.1128/AAC.05150-14. Epub 2015 Apr 20.

20.

The Pseudomonas aeruginosa CreBC two-component system plays a major role in the response to β-lactams, fitness, biofilm growth, and global regulation.

Zamorano L, Moyà B, Juan C, Mulet X, Blázquez J, Oliver A.

Antimicrob Agents Chemother. 2014 Sep;58(9):5084-95. doi: 10.1128/AAC.02556-14. Epub 2014 Jun 16.

21.

Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A.

Antimicrob Agents Chemother. 2014 Jun;58(6):3091-9. doi: 10.1128/AAC.02462-13. Epub 2014 Mar 17.

22.

Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing.

Martínez-Ramos I, Mulet X, Moyá B, Barbier M, Oliver A, Albertí S.

Antimicrob Agents Chemother. 2014;58(4):2426-9. doi: 10.1128/AAC.02012-13. Epub 2014 Jan 13.

23.

Biological markers of Pseudomonas aeruginosa epidemic high-risk clones.

Mulet X, Cabot G, Ocampo-Sosa AA, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2013 Nov;57(11):5527-35. doi: 10.1128/AAC.01481-13. Epub 2013 Aug 26.

24.

Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection.

López-Causapé C, Rojo-Molinero E, Mulet X, Cabot G, Moyà B, Figuerola J, Togores B, Pérez JL, Oliver A.

PLoS One. 2013 Aug 12;8(8):e71001. doi: 10.1371/journal.pone.0071001. eCollection 2013.

25.

Evaluation of a heredofamilial cancer unit in increasing family history collection and genetic counseling referrals among Spanish oncologists at a university hospital.

Márquez-Rodas I, López-Tarruella S, Jerez Y, Cavanagh M, Custodio S, López-Trabada D, Moya B, Pérez S, Rupérez AB, Martín M.

J Genet Couns. 2014 Feb;23(1):108-13. doi: 10.1007/s10897-013-9617-z. Epub 2013 Jun 16.

PMID:
23771728
26.

Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones.

Cabot G, Ocampo-Sosa AA, Domínguez MA, Gago JF, Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2012 Dec;56(12):6349-57. doi: 10.1128/AAC.01388-12. Epub 2012 Oct 8.

27.

Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.

Moyá B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A.

Antimicrob Agents Chemother. 2012 Sep;56(9):4771-8. doi: 10.1128/AAC.00680-12. Epub 2012 Jun 25.

28.

H1N1 influenza virus-associated encephalitis: a case report.

Joosten A, Moya B, Nunes J, Germano N, Alcântara J, Bento L.

Med Intensiva. 2012 Oct;36(7):520-2. doi: 10.1016/j.medin.2012.01.002. Epub 2012 Mar 3. No abstract available.

29.

Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study.

Ocampo-Sosa AA, Cabot G, Rodríguez C, Roman E, Tubau F, Macia MD, Moya B, Zamorano L, Suárez C, Peña C, Domínguez MA, Moncalián G, Oliver A, Martínez-Martínez L; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2012 Apr;56(4):1703-13. doi: 10.1128/AAC.05451-11. Epub 2012 Jan 30.

30.

Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth.

Mulet X, Moyá B, Juan C, Macià MD, Pérez JL, Blázquez J, Oliver A.

Antimicrob Agents Chemother. 2011 Oct;55(10):4560-8. doi: 10.1128/AAC.00519-11. Epub 2011 Aug 1.

31.

AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.

Zamorano L, Reeve TM, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.

Antimicrob Agents Chemother. 2011 May;55(5):1990-6. doi: 10.1128/AAC.01688-10. Epub 2011 Feb 28.

32.

Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.

Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2011 May;55(5):1906-11. doi: 10.1128/AAC.01645-10. Epub 2011 Feb 28.

33.

NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.

Zamorano L, Reeve TM, Deng L, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.

Antimicrob Agents Chemother. 2010 Sep;54(9):3557-63. doi: 10.1128/AAC.00385-10. Epub 2010 Jun 21.

34.

Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.

Moyá B, Zamorano L, Juan C, Ge Y, Oliver A.

Antimicrob Agents Chemother. 2010 Sep;54(9):3933-7. doi: 10.1128/AAC.00296-10. Epub 2010 Jun 14.

35.

Differential beta-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains.

Zamorano L, Moyá B, Juan C, Oliver A.

J Antimicrob Chemother. 2010 Jul;65(7):1540-2. doi: 10.1093/jac/dkq142. Epub 2010 Apr 30. No abstract available.

PMID:
20435778
36.

Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A.

Antimicrob Agents Chemother. 2010 Mar;54(3):1213-7. doi: 10.1128/AAC.01104-09. Epub 2010 Jan 19.

37.

Utility of intravascular ultrasound examination during carotid stenting.

Joan MM, Moya BG, Agustí FP, Vidal RG, Arjona YA, Alija MP, Paredero VM.

Ann Vasc Surg. 2009 Sep-Oct;23(5):606-11. doi: 10.1016/j.avsg.2008.09.010. Epub 2009 Jun 24.

PMID:
19556101
38.

Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.

Peña C, Suarez C, Tubau F, Juan C, Moya B, Dominguez MA, Oliver A, Pujol M, Ariza J.

J Clin Microbiol. 2009 Aug;47(8):2381-7. doi: 10.1128/JCM.00094-09. Epub 2009 Jun 3.

39.

Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2.

Oteo J, Diestra K, Juan C, Bautista V, Novais A, Pérez-Vázquez M, Moyá B, Miró E, Coque TM, Oliver A, Cantón R, Navarro F, Campos J; Spanish Network in Infectious Pathology Project (REIPI).

Int J Antimicrob Agents. 2009 Aug;34(2):173-6. doi: 10.1016/j.ijantimicag.2009.03.006. Epub 2009 May 22. Erratum in: Int J Antimicrob Agents. 2010 Nov;36(5):483.

PMID:
19464856
40.

Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein.

Moya B, Dötsch A, Juan C, Blázquez J, Zamorano L, Haussler S, Oliver A.

PLoS Pathog. 2009 Mar;5(3):e1000353. doi: 10.1371/journal.ppat.1000353. Epub 2009 Mar 27.

41.

Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae.

Diestra K, Juan C, Curiao T, Moyá B, Miró E, Oteo J, Coque TM, Pérez-Vázquez M, Campos J, Cantón R, Oliver A, Navarro F; Red Española de Investigación en Patología Infecciosa (REIPI), Spain.

J Antimicrob Chemother. 2009 Jan;63(1):60-6. doi: 10.1093/jac/dkn453. Epub 2008 Nov 6.

PMID:
18988679
42.

[Characterization and molecular epidemiology of ESBL in Escherichia coli and Klebsiella pneumoniae in 11 Spanish hospitals (2004)].

Diestra K, Coque TM, Miró E, Oteo J, Nicolau CJ, Campos J, Moyá B, Curiao T, Pérez-Vázquez M, Cantón R, Oliver A, Navarro F; Red Española de Investigación en Patología Infecciosa.

Enferm Infecc Microbiol Clin. 2008 Aug-Sep;26(7):404-10. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2010 Oct;28(8):575.

PMID:
18842234
43.

Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa.

Moya B, Juan C, Albertí S, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2008 Oct;52(10):3694-700. doi: 10.1128/AAC.00172-08. Epub 2008 Jul 21.

44.

Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2007 Jul;51(7):2574-81. Epub 2007 Apr 30.

45.

Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice.

Mena A, Maciá MD, Borrell N, Moya B, de Francisco T, Pérez JL, Oliver A.

J Bacteriol. 2007 May;189(9):3665-8. Epub 2007 Feb 16.

46.
47.

Transcervical falloposcopy: preliminary experience.

Pennehouat G, Risquez F, Naouri M, Thebault Y, Guglielmina JN, Deval B, Moya B, Madelenat P.

Hum Reprod. 1993 Mar;8(3):445-9.

PMID:
8473465

Supplemental Content

Support Center